Therapeutic effect of recombinant interleukin-2 against chronic hepatitis type B.

概要

論文の詳細を見る
Responses of peripheral mononuclear cells and T cells from patients with chronic hepatitis (CH) type B to recombinant interleukin-2 (rIL-2) were examined. Changes of viral and immunological markers following intravenous administration of rIL-2 against patients with CH type B were examined simultaneously. Mononuclear cells and T cells from patients with CH type B responded to rIL-2 in the same degree as those from normal controls. Immediately after intravenous drip infusion of rIL-2, the number of peripheral lymphocytes and Leu11+ cells decreased significantly in the all 7 patients with CH type B. NK activity decreased significantly in 5 of 7 patients with CH type B, and the OKT4/OKT8 ratio increased significantly in the all 7 patients with CH type B. In 6 of 9 patients to whom rIL-2 was administered for 7 or 28 days, the activity of DNA-polymerase decreased during treatment.<BR>It was considered that in vivo effect of IL-2 on patients with CH type B is attributed to an antiviral action through hitherto unexplained immunological affairs.